Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.
marketbeat.comAkebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Nearmarketbeat.comJun 4
globenewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 1
globenewswire.comAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conferenceglobenewswire.comMay 28
seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7
zacks.comAkebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimateszacks.comMay 7